Cargando…
Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells
Everolimus inhibits mammalian target of rapamycin (mTOR) and leads to decreased protein synthesis and decreased cancer cell proliferation in many experimental systems. Adenosine 5′-monophosphate-activated protein kinase (AMPK) activators such as metformin have similar actions in keeping with the TSC...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cognizant Communication Corporation
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838426/ https://www.ncbi.nlm.nih.gov/pubmed/26351208 http://dx.doi.org/10.3727/096504015X14348950540999 |